1. EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke
In patients with T2DM and at high risk of CV events, in addition to standard care
Placebo
Empagliflozin
Patients with Event (%)
P=0.04 for superiority
Hazard ratio, 0.86 (95.02% CI, 0.74–0.99)
Month
Adapted from: Zinman et al., NEJM 2015

2. EMPA-REG OUTCOME: cumulative incidence of death from CV causes
In patients with T2DM and at high risk of CV events, in addition to standard care
Placebo
Patients with Event (%)
Empagliflozin
P<0.001
Hazard ratio, 0.62 (95% CI, 0.49–0.77)
Month
Adapted from: Zinman et al., NEJM 2015

3. EMPA-REG OUTCOME: Death from any cause
In patients with T2DM and at high risk of CV events, in addition to standard care
Placebo
Patients with Event (%)
Empagliflozin
P<0.001
Hazard ratio, 0.68 (95% CI, 0.57–0.82)
Month
Adapted from: Zinman et al., NEJM 2015

4. EMPA-REG OUTCOME: Hospitalization for Heart Failure
In patients with T2DM and at high risk of CV events, in addition to standard care
Placebo
Patients with Event (%)
Empagliflozin
P=0.002
Hazard ratio, 0.65 (95% CI, 0.50–0.85)
Month
Adapted from: Zinman et al., NEJM 2015